Trial · NCT00059332

Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial

NCT00059332, Phase 3, Completed, Jeffrey L. Saver; results first posted 2015-08-21

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial. Trials, record NCT00059332. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00059332

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial
NCT number: NCT00059332
Status: Completed
Phases: Phase 3
Enrollment: 1,700 participants, actual
Lead sponsor: Jeffrey L. Saver
Conditions: Cerebrovascular Accident
Interventions: Magnesium Sulfate, Normal Saline
First posted: 2003-04-24
Last updated: 2015-08-21
Results first posted: 2015-08-21

Source ClinicalTrials.gov

Registered outcomes9

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Modified Rankin Scale	3 months after stroke onset	Modified Rankin Scales (mRS) is a measure of global disability. Total Scale range is 0-6, with lower values indicating better outcomes. 0 No symptoms at all 1. No significant disability despite symptoms; able to carry out all usual duties and activities 2. Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. Moderate disability; requiring some help, but able to walk without assistance 4. Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance 5. Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. Dead
Secondary	Modified Rankin Score of 0 or 1	3 months	Minimal or no disability based on the modified Rankin score
Secondary	Modified Rankin Score ≤2	3 months	Functional independence based on modified Rankin score
Secondary	NIH Stroke Scale	3 months	The National Institute of Health Stroke Scale (NIHSS) is a measure of neurologic deficit. Total Score range 0-42, with higher scores indicating greater severity. The 11 domains assessed are: 1a-c Level of consciousness 2. Best Gaze 3. Visual 4. Facial Palsy 5a. Motor left arm 5b. Motor right arm 6a. Motor left leg 6b. Motor right leg 7. Limb Ataxia 8. Sensory 9. Best Language 10. Dysarthria 11. Extinction and Inattention
Secondary	Barthel Index	3 months	The Barthel Index is a measure of activities of daily living. Total score is calculated by addition of subscale scores. Total score range is 0-100, with higher scores indicating better outcomes. The ten subitems are: FEEDING (Subscale range is 0-10) BATHING (Subscale range is 0-5) GROOMING (Subscale range is 0-5) DRESSING (Subscale range is 0-10) BOWELS (Subscale range is 0-10) BLADDER (Subscale range is 0-10) TOILET USE (Subscale range is 0-10) TRANSFERS (Subscale range is 0-15) MOBILITY (Subscale range is 0-15) STAIRS (Subscale range is 0-10)
Secondary	Stroke Impact Scale	3 months	The Stroke Impact Scale (SIS) is a measure of stroke-specific quality of life. The scale assesses 8 domains. Scores for each domain range from 0-100, with higher scores indicating better outcomes. 1. Physical problems 2. Memory and thinking 3. Mood and emotions 4. Communication, reading and understanding 5. Daily activities 6. Mobility at home and in the community 7. Affected hand use 8. Hobbies and activities participation
Secondary	Serious Adverse Events	3 months
Secondary	Symptomatic Intracranial Hemorrhage	3 month
Secondary	Mortality	3 months

Source ClinicalTrials.gov

Outcomes9

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Modified Rankin Scale	3 months after stroke onset	units on a scale	MEDIAN
SECONDARY	Modified Rankin Score of 0 or 1	3 months	participants	NUMBER
SECONDARY	Modified Rankin Score ≤2	3 months	participants	NUMBER
SECONDARY	NIH Stroke Scale	3 months	units on a scale	MEDIAN
SECONDARY	Barthel Index	3 months	units on a scale	MEDIAN
SECONDARY	Stroke Impact Scale	3 months	units on a scale	MEDIAN
SECONDARY	Serious Adverse Events	3 months	participants	NUMBER
SECONDARY	Symptomatic Intracranial Hemorrhage	3 month	participants	NUMBER
SECONDARY	Mortality	3 months	participants	NUMBER

Source ClinicalTrials.gov

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Modified Rankin Scale	Normal Saline	2	Inter-Quartile Range 1 to 4	units on a scale
Modified Rankin Scale	Magnesium Sulfate	2	Inter-Quartile Range 1 to 5	units on a scale
Modified Rankin Score of 0 or 1	Normal Saline	311		participants
Modified Rankin Score of 0 or 1	Magnesium Sulfate	313		participants
Modified Rankin Score ≤2	Normal Saline	445		participants
Modified Rankin Score ≤2	Magnesium Sulfate	449		participants
NIH Stroke Scale	Normal Saline	3	Inter-Quartile Range 0 to 42	units on a scale
NIH Stroke Scale	Magnesium Sulfate	3	Inter-Quartile Range 0 to 19	units on a scale
Barthel Index	Normal Saline	95	Inter-Quartile Range 20 to 100	units on a scale
Barthel Index	Magnesium Sulfate	90	Inter-Quartile Range 30 to 100	units on a scale

1 to 10 of 18Source ClinicalTrials.gov

See all 18 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Normal Saline	843
Overall Study	STARTED	Magnesium Sulfate	857
Overall Study	COMPLETED	Normal Saline	840
Overall Study	COMPLETED	Magnesium Sulfate	855
Overall Study	NOT COMPLETED	Normal Saline	3
Overall Study	NOT COMPLETED	Magnesium Sulfate	2

Source ClinicalTrials.gov

Adverse events442

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Headache	General disorders	Normal Saline	167	843	173
other	Headache	General disorders	Magnesium Sulfate	178	857	184
other	Hypokalaemia	Blood and lymphatic system disorders	Normal Saline	214	843	233
other	Hypokalaemia	Blood and lymphatic system disorders	Magnesium Sulfate	205	857	217
other	Urinary tract infection	Renal and urinary disorders	Normal Saline	133	843	142
other	Urinary tract infection	Renal and urinary disorders	Magnesium Sulfate	138	857	152
serious	Anemia	Blood and lymphatic system disorders	Normal Saline	8	843
serious	Anemia	Blood and lymphatic system disorders	Magnesium Sulfate	12	857
serious	Disseminated intravascular coagulation	Blood and lymphatic system disorders	Normal Saline	0	843
serious	Disseminated intravascular coagulation	Blood and lymphatic system disorders	Magnesium Sulfate	1	857

1 to 10 of 442Source ClinicalTrials.gov

See all 442 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Normal Saline
Total, all-cause mortality	Magnesium Sulfate
Total, other adverse events	Normal Saline	331	843
Total, other adverse events	Magnesium Sulfate	329	857
Total, serious adverse events	Normal Saline	422	843
Total, serious adverse events	Magnesium Sulfate	439	857

Source ClinicalTrials.gov

Papers14

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
25651247	DERIVED	PubMed
26265130	DERIVED	PubMed
26658446	DERIVED	PubMed
27679533	DERIVED	PubMed
28389617	DERIVED	PubMed
29301973	DERIVED	PubMed
30039165	DERIVED	PubMed
31955642	DERIVED	PubMed
32038463	DERIVED	PubMed
35380053	DERIVED	PubMed

1 to 10 of 14

See all 14 papers

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U01NS044364	Field Administration of Stroke Therapy-Magnesium Trial (FAST-MAG)	SAVER, JEFFREY L	UNIVERSITY OF CALIFORNIA LOS ANGELES	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE	2003 to 2013

Source NIH RePORTER

Trial comparisons6

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Normal Saline vs Magnesium Sulfate: Modified Rankin Score ≤2	Trial comparisons
Normal Saline vs Magnesium Sulfate: Mortality	Trial comparisons
Normal Saline vs Magnesium Sulfate: Symptomatic Intracranial Hemorrhage	Trial comparisons
Normal Saline vs Magnesium Sulfate: Serious Adverse Events	Trial comparisons
Normal Saline vs Magnesium Sulfate: Modified Rankin Score of 0 or 1	Trial comparisons
Normal Saline vs Magnesium Sulfate: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00059332

GET https://conductscience.org/api/trials/v1/NCT00059332/events?page=2

API reference For AI assistants